Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > REGULATORY
REGULATORY
- MHLW Panel OKs 60 More Health Damage Claims for COVID-19 Vaccines
July 29, 2022
- Japan Detects 2nd Monkeypox Case in Tokyo
July 29, 2022
- Supply Chain Clause of Economic Security Law to Be Enforced on Aug. 1
July 28, 2022
- MHLW Eyes Omicron-Specific Jabs for All Residents Given Primary Inoculations
July 26, 2022
- Panel OKs COVID-Flu Shots to Be Given Simultaneously
July 26, 2022
- Japan Panel Recognizes 1st Death Linked to COVID Vaccination
July 26, 2022
- 8 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 26, 2022
- Japan Confirms 1st Monkeypox Case
July 26, 2022
- 4th COVID Jabs Approved for Healthcare Providers: MHLW
July 25, 2022
- Omicron-Specific Boosters to Be Introduced This Fall or Later: Panel
July 25, 2022
- KM Biologics’s Smallpox Vaccine Up for Review for Monkeypox Use
July 25, 2022
- Japan to Boost Measures to Ensure COVID Drug Access, Govt Says after Shionogi Antiviral Delay
July 22, 2022
- Label Expansions for Onoact, Ultomiris Up for MHLW Panel Review on Aug. 4
July 22, 2022
- Komeito Lawmakers Call for Assessing Shionogi’s Pill for Circulating Strains
July 22, 2022
- Japan Plans Smaller Drug Price Survey for 2023 Revision, Just Like 2 Years Ago
July 21, 2022
- Imfinzi, Bavencio to Add Encephalitis Risks in Label Revision
July 21, 2022
- Janssen’s CAR-T Therapy, Kymriah Label Expansion Up for Review on Aug. 3
July 21, 2022
- Novo’s Rybelsus in for Price Cuts as Chuikyo OKs CEA Results
July 21, 2022
- Nuvaxovid Gets Label Update to Allow Primary Inoculations in Ages 12 and Older
July 21, 2022
- Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…